Diagnostics and therapy of diseases associated with HHV-8...

Details Diagnostics and therapy of diseases associated with HHV-8... Diagnostics and therapy of diseases associated with HHV-8...

2001-05-16

2003-01-07

Salimi, Ali R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S204100, C435S005000, C435S007100, C435S006120, C530S300000, C530S350000, C536S023720

Reexamination Certificate

active

06503513

ABSTRACT:

The present invention is directed to monoclonal antibodies capable of specifically recognizing an antigenic determinant (epitope) of the protein kaposin or a derivative therof and capable of binding thereto, hybridoma cell lines producing said monoclonal antibodies, diagnostic systems for the detection of the presence of a kaposin protein or a derivative thereof as well as antibodies directed against kaposin protein or a derivative thereof, methods for detection of the expression of kaposin protein or a derivative thereof in a biological sample, methods for the detection of antibodies directed against kaposin protein or a derivative thereof, uses of the monoclonal antibodies provided according to the invention and uses of kaposin protein or a derivative thereof, each in diagnostics and therapy.
BACKGROUND OF THE INVENTION
The human herpes virus 8 has been detected in all forms of Kaposi's sarcoma, in primary effusion lymphomas (PEL), in Castleman's disease, in angiosarcomas, in skin lesions of patients who underwent transplantations, in plasmacytomas, sarcoidosis as well as in healthy control individuals (Chang et al., 1994; Boshoff and Weiss, 1997). Seroepidemiological studies have shown that in northern and central Europe HHV-8 is substantially restricted to risk groups and that there are large differences with respect to geography and age.
Moreover, these studies were able to show that in patients with Kaposi's sarcomas a seroconversion for HHV-8 is detectable months to years prior to the diagnosis of Kaposi's sarcoma and that it is likely that HHV-8 is transferred primarily via sexual.contacts. To date, the clinical signs of a primary HHV-8 infection are unknown. Due to the detection of HHV-8 in almost 100% of all Kaposi's sarcomas, the correlation of the regional seroprevalence with the incidence of HHV-8 and the seroconversion prior to the appearence of Kaposi's sarcoma it is believed today that HHV-8 at least represents a co-factor in the tumorigenesis of KS. Up to now, the role of HHV-8 in the other diseases mentioned above is unclear and the question whether HHV-8 is involved in other so far unidentified diseases is still unanswered.
Taxonomically, on the basis of sequence homologies HHV-8 belongs to the gamma herpes virus sub-family and is closely related to EBV and
Herpesvirus saimiri.
The HHV-8 genome is 140 kb in size and is flanked by several repetitive sequences having a length of approximately 800 bp (Russo et al., 1996). HHV-8 codes for about 80 proteins, 10 of which show homology to cellular gene products (Neipel et al., 1997). Similar to all other herpes viruses, HHV-8 is able to cause a lytic infection which then becomes a latent infection. In the latent phase, at least two viral transcripts are expressed: a differentially spliced mRNA encoding the v-cyclin, v-flip and LANA proteins, as well as T0.7, a short RNA 0.7 kb in length and of up to now unknown function (Zhong et al., 1996). The viral transcript T0.7. is the most abundant of the RNAs expressed in the latent phase and has three open reading frames corresponding to 60, 35, and 47 amino acids.
So far, a HHV-8 infection has been detected by polymerase chain reaction using HHV-8-specific oligonucleotide primers. This direct method of detection has disadvantages in that it (i) requires at lot of effort and costs (about five to ten times the price of serological detection), (ii) is susceptible to false positive results due to contamination, (iii) detects only acute infections but not earlier ones, and (iv) detects only 50% of all (acutely) infected subjects if used on peripheral blood.
The serological detection methods developed so far are based on either the use of HHV-8-infected cell lines or on recombinant viral proteins. Assays detecting the antibodies directed against HHV-8 on HHV-8-positive cell lines by means of immunofluorescence have the disadvantages that (i) their reproducibility is low (i.a. because it is impossible to keep the culture conditions for the HHV-8 cell lines absolutely constant), (ii) their evaluation may not be performed by machine which makes them unsuitable for a larger number of tests, and (iii) it is in part difficult to exclude cross-reactions of antibodies against other viruses. A common problem of all of the assays based on recombinant viral proteins is their low sensitivity. This problem is based on the fact that antibodies are produced only against particular proteins of the virus and that different individuals may in part produce antibodies against different proteins. The viral proteins tested to date for their utility in serological diagnostics have a sensitivity of only between 30 and 80%.
FIG. 1
exemplarily shows that antibodies against the minor capsid protein VP23 can be detected in only 30% of KS patients (FIG.
1
). It is highly likely that the use of more than one viral protein is required in order to develop more sensitive assays.
Since with respect to its frequency Kaposi's sarcoma is in third place of the tumors occuring after an organ transplantation and according to current knowledge its occurence is closely associated to HHV-8 infection it may be expected that in the future organ donors and possibly also blood products will be tested for HHV-8 similar to e.g. the obligatory testing for HIV, hepatitis B and C which is performed today.
In part, the dignity of KS is highly variable. The KS which does not occur endemically is almost exclusively restricted to the immunodeficient patient and generally has a malignant course. It is treated by chemotherapy (such as liposomal doxorubicin), surgically or by means of radiotherapy with modest success. Retrospective studies indicate that the virostatics Foscarnet and Gancyclovir are effective. Larger prospective studies with regard to the effectivity of virostatics on KS have not been published to date. Also missing up to now is a uniform treatment schedule for the B cell lymphomas in which HHV-8 has been detected. Chemotherapeutic schedules have been widely used which were generally employed in the treatment of Non-Hodgekin lymphomas.
SUMMARY OF THE INVENTION
Therefore, it is an object of the present invention to provide novel means for the diagnostics and therapy of HHV-8 infections and of dieseases directly or indirectly caused by HHV-8.
According to the invention, this object has been achieved by the monoclonal antibodies characterized in claim 1 as well as by the hybridoma cell lines, diagnostic systems, methods of detection, and uses characterized in more detail in the dependent claims. Preferred embodiments of the invention are obvious from the dependent claims.
According to the invention, there are provided monoclonal antibodies specifically recognizing an epitope of the kaposin protein or a derivative thereof and binding to said epitope. An “epitope” according to the invention is intended to mean an antigenic determinant of kaposin peptide or protein or a derivative thereof which may be recognized by a monoclonal antibody and to which the monoclonal antibody can bind.
The derivative of kaposin peptide comprises an amino acid sequence of kaposin peptide formed by deletion, substitution, insertion, addition and/or chemical modification of one or more amino acid(s) provided that the antibody directed against an epitope of the derivative of kaposin peptide is useful for the specific detection of a HHV-8 infection.
The monoclonal antibody provided by the invention recognizes an epitope in the cytoplasmic region or the extracellular region of kaposin protein or a derivative thereof.
The monoclonal antibodies used in the present invention are specifically directed against an epitope of one of the following peptides:
(a) AIPPLVCLLA (SEQ ID NO:13); or
(b) QRGPVAFRTRVATG (SEQ ID NO:23).
A further embodiment also comprises the following sequence QRGPVAFRTRVA (SEQ ID NO:24), composed of the peptides 15 and 16 of Table 1.
In another embodiment of the invention the monoclonal antibody is directed against a peptide fragment (a derivative) thereof having a length of at least 5, at least

Affiliated with

Also associated with

Rating

Diagnostics and therapy of diseases associated with HHV-8... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnostics and therapy of diseases associated with HHV-8..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostics and therapy of diseases associated with HHV-8... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3057482